TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04080167

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: InCharge Health mobile application
Description: The InCharge Health app features include: Daily reminders; Ability to customize content of message and time of day when the message comes; Symptom tracker to monitor daily pain and mood; 7-day streak that tracks daily adherence; Graphing adherence against pain symptoms; Communication feature allowing the patient to connect to the clinic and a health partner; Link to discussion forum where communication to other patients can occur; Education bank that provides information about SCD and hydroxyurea. Participants can delay daily push notifications. If hospitalized, participants may stop notifications. A special feature of the app is to set up a health partner, who may be a person the participant may choose from his/her contact list and who will receive notifications if it had been \<4 hours since not documenting the use of hydroxyurea. The app healthy partner will be encouraged to message the participant to remind him/her to take the medication.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HU Toolbox mobile application
Description: The HU Toolbox app includes algorithms for hydroxyurea use and is ready for immediate use on Apple and Android operating systems. In addition, it has the NHLBI guidelines adapted for pediatrics (guidelines/recommendations separated by age) and for adults (guidelines/ recommendations separated by organ system, laboratory, or physical exam finding). The HU Toolbox app includes the ability to search guidelines for key words and add notes. Algorithms are also included as PDF documents that can be printed out or emailed. Finally, a contact list of local SCD specialists and important contacts is included, so providers can easily contact SCD experts and expect an answer in 24 hours or less. The HU Toolbox app is easily updated with all data and resources stored on a cloud-based server that can provide instant up-to-date information to those using the app.
Study: NCT02528812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraBand Roller Massager
Description: The roller massager was moved proximal to distal at a slow pace (2 seconds up and 2 second downs) over the muscle belly. Participants in the Sham group received very light pain-free cutaneous strokes of rolling massage with the same pace of rolling as performed for the Ipsi-R and Contra-R groups. The Control group did not receive any treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraBand Roller Massager
Description: The roller massager was moved proximal to distal at a slow pace (2 seconds up and 2 second downs) over the muscle belly. Participants in the Sham group received very light pain-free cutaneous strokes of rolling massage with the same pace of rolling as performed for the Ipsi-R and Contra-R groups. The Control group did not receive any treatment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TheraBand Roller Massager
Description: The roller massager was moved proximal to distal at a slow pace (2 seconds up and 2 second downs) over the muscle belly. Participants in the Sham group received very light pain-free cutaneous strokes of rolling massage with the same pace of rolling as performed for the Ipsi-R and Contra-R groups. The Control group did not receive any treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Massage
Description: A massage therapist massaged the participant
Study: NCT00111852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmoteplase
Description: Desmoteplase 90 mcg/kg, intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmoteplase
Description: Desmoteplase 125 mcg/kg, intravenous administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-Match Placebo, intravenous administration.
Study: NCT03339219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib tablets
Study: NCT00520806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relaxin
Description: Intravenous infusion for 48 h at 30 ug/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion for 48 h
Study: NCT01526681

Intervention type: OTHER
Intervention: Processed Human Nerve Graft
Description: Implantation of appropriate length of processed human nerve graft at the time of surgery

Intervention type: OTHER
Intervention: Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc.
Description: Historical control from established literature

Intervention type: OTHER
Intervention: Autogenous Nerve Graft
Description: Nerve gap reconstructions with autogenous nerve graft within the upper extremity

Intervention type: DEVICE
Intervention: Nerve Tube Conduit
Description: Nerve gap reconstructions with nerve tube conduit within the upper extremity

Intervention type: PROCEDURE
Intervention: Autologous Breast Reconstruction with Neurotization

Intervention type: PROCEDURE
Intervention: Autologous Breast Reconstruction without Neurotization
Study: NCT00629343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine In Combination With Temozolomide
Description: mg, oral
Study: NCT04749056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPAS (electronic psycho-oncological adapative screening program)
Description: Adaptive tests assess depression, anxiety and distress. Only items with highest information value are selected. Furthermore, patients fill in a checklist to report supportive care needs.~The results page contains (i) the extent of distress and additional information to interpret these levels, (ii) a summary of the reported supportive care needs and (iii) individualized recommendations for the use of psychosocial services at the institution based on the care needs.~The supportive care needs are transformed into concrete recommendations to use the adequate psychosocial service at the institution. Highly distressed patients are recommended to use psycho-oncological service irrespective of whether they have reported such a need in the check list. Physicians of highly distressed patients are recommended on their results page to talk with the patient about his/her psychosocial condition and further issues within such an appointment are suggested.
Study: NCT02858505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 27 mg elemental iron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 54 mg elemental iron
Study: NCT01279785

Intervention type: DRUG
Intervention: 123I-MIP-1072
Description: Single IV dose
Study: NCT02681978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Ivabradine 5 mg twice daily

Intervention type: DRUG
Group type: OTHER
Intervention: Standard medical therapy
Description: Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical therapy
Description: Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
Study: NCT00505349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive training
Description: The experimental cognitive training program consists of interactive training exercises in which the participant responds to visual patterns and stimuli. The program is designed upon the principles of brain-plasticity, and, for the purposes of this study, is intended to be used for an 8-10 week period (40 total hours of training.)
Study: NCT03393988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl infusion
Description: After induction of general anesthesia; Fentanyl infusion (0.5 µg/kg/hr) will be started (which will be afterwards adjusted intraoperatively according to the hemodynamics and Bispectral Index (BIS) reading).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl infusion
Description: After induction of general anesthesia; Fentanyl infusion (0.5 µg/kg/hr) will be started (which will be afterwards adjusted intraoperatively according to the hemodynamics and Bispectral Index (BIS) reading).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided TAP block
Description: After induction of general anesthesia; Patients will receive ultrasound guided subcostal oblique TAP block with 0.25 % bupivacaine 40 ml on each side resulting in a total volume of 80 ml, subcostal TAP block was given twice, at the beginning and at the end of the surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine (200 µg in 2 ml diluted in 48 ml of saline) will be started in a dose of 1 μg/kg over 10 min then maintenance dose as continuous infusion between 0.2 and 0.8 μg/ kg/h through infusion pump (which will be adjusted according to the hemodynamics and BIS reading)
Study: NCT00641368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: R4Power Program
Description: In the 10-lesson online R4Power Program, adolescents will learn cognitive skills (link between thoughts, feelings, and behaviors; thinking traps; challenging negative beliefs) and problem-solving skills (assertiveness; relaxation and distraction; overcoming procrastination; decision-making) in order to cope with stressful situations.

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control
Description: Adolescents in the waitlist control group will complete the R4Power program during the second year of the study.
Study: NCT00080236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDN-6556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDN-6556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDN-6556

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT01099332

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gastro-retentive zinc cysteine tablet
Description: Oral, one tablet, once daily with water for 6 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tablet identical physically to active comparator containing some lactose
Description: Oral, once daily, with water, 6 months.
Study: NCT04205383

Intervention type: OTHER
Intervention: biological analyses
Description: The histones H3-citrullinated, acetylated histones (Pan-histones), H1 histone as well as the free HMGB1 protein will be quantified. This choice corresponds to the histones involved in inflammation, proliferation, migration or cell differentiation and can be quantified to date.

Intervention type: OTHER
Intervention: biological analyses
Description: The histones H3-citrullinated, acetylated histones (Pan-histones), H1 histone as well as the free HMGB1 protein will be quantified. This choice corresponds to the histones involved in inflammation, proliferation, migration or cell differentiation and can be quantified to date.

Intervention type: OTHER
Intervention: biological analyses
Description: The histones H3-citrullinated, acetylated histones (Pan-histones), H1 histone as well as the free HMGB1 protein will be quantified. This choice corresponds to the histones involved in inflammation, proliferation, migration or cell differentiation and can be quantified to date.
Study: NCT04141436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventions Based on Hypnofertility
Description: Affirmation Visualization Imagination Relaxation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine clinical procedure
Description: Routine clinical procedure
Study: NCT00078897

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Selenium
Description: Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selenium
Description: Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.
Study: NCT01839669

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foot Orthoses Only
Description: patients wear foot orthoses as a treatment condition - no further therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Foot Orthoses and Eccentric Exercise
Description: patients wear foot orthoses and they perform an additional home-based eccentric training program for the M. tibialis posterior

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Foot Orthoses
Description: patient wear sham foot orthoses (control condition)
Study: NCT03241368

Intervention type: DEVICE
Group type: OTHER
Intervention: Capsule Endoscopy
Description: At baseline subject will under the PillCam Crohn's Capsule Procedure
Study: NCT01642784

Intervention type: DEVICE
Intervention: Primary PCI of culprit lesion in IRA with drug eluting stent (DES)
Description: Primary PCI of culprit lesion in IRA with drug eluting stent (DES)

Intervention type: DEVICE
Intervention: Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES
Description: Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES
Study: NCT02693132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised (SUP-PA)
Description: Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of supervised moderate-to-vigorous intensity physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unsupervised (UNSUP-PA)
Description: Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of unsupervised moderate-to-vigorous intensity physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step-based (STEP)
Description: Weight loss intervention that involves an energy restricted diet plus the inclusion of physical activity in the form of 10,000 steps/day with 2,500 brisk steps/day.
Study: NCT01482052

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: meningococcal meningitis conjugate vaccine, quadrivalent
Description: NmVac4-A/C/Y/W-135-DT™conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 16 µg total diphtheria toxoid.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: meningococcal meningitis conjugate vaccine, quadrivalent
Description: Meningococcal (Groups A,C,Y and W-135-DT) Polysaccharide Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 48 µg total diphtheria toxoid.
Study: NCT01247272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine Hydrochloride
Description: 90 mg Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROZAC WEEKLY®
Description: 90 mg Capsules
Study: NCT00405600

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Device used in surgery with or without instrumentation
Description: Infuse Bone Graft BMP-2, Large Kit will be used in all surgeries. Spine surgeries will be either instrumented or uninstrumented.
Study: NCT03251313

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: JS001 120mg+GP
Description: In this arm, JS001 120mg will be given at d1; Gem 1000mg/m2 d2,9; DDP(cisplatin) 75mg/m2 d2

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: JS001 240mg+GP
Description: In this arm, JS001 240mg will be given at d1; Gem 1000mg/m2 d2,9; DDP 75mg/m2 d2

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: JS001 480mg+GP
Description: In this arm, JS001 480mg will be given at d1; Gem 1000mg/m2 d2,9; DDP 75mg/m2 d2

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GP followed by JS001
Description: In this arm,Patients receive 6 cycles of GP without JS001 and then receive JS001 maintenance therapy for up to approximately 2 years. JS001 will be given at RP2D.
Study: NCT01032252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: 16 week exercise once a week of 60 minutes intervention by trained fall prevention instructors and a home program.~Intervention includes strength/power training, balance/gait training, behavioral aspects and perceptual and functional training.
Study: NCT04150861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Delta
Description: Solution for Injection, subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Delta
Description: Solution for Injection, subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Delta
Description: Solution for Injection, subcutaneous administration
Study: NCT04615026

Intervention type: DIAGNOSTIC_TEST
Intervention: duplex sonography
Description: all patients with consent receive a duplex ultrasound, blood test, cognitive test and test of smelling
Study: NCT01349400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watchful waiting
Description: Watchful waiting means the observation of the hernia. The patient is informed about signs of deterioration or incarceration. The hernia is controlled clinically on defined follow-up visits.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hernia repair
Description: Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided.~These are all standard techniques in incisional hernia repair.
Study: NCT03613519

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SHUTi
Description: A woman assigned to SHUTi receives access to an online program that includes 6 interactive sessions that are designed to be reviewed over a period of about 8 weeks. The online sessions include videos and written material that give information about factors that affect sleep, changes that might help sleep patterns, and how to make those changes. Each session takes about 45 to 60 minutes to complete. During and between sessions, the participant fills out sleep diaries to gather information about daily sleep patterns. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health as well as sleep diaries. Time 1 is just before starting the first session of the SHUTi program. Time 2 is about 9 weeks later and Time 3 is about six months after that. The questionnaires will be used to assess the effect of the online program on the participant's sleep and health.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: modified SHUTi (i.e., SHUTi-BWHS)
Description: A woman assigned to modified SHUTi (i.e., to SHUTi-BWHS) receives access to an online program that includes 6 interactive sessions that are designed to be reviewed over a period of about 8 weeks. The online sessions include videos and written material that give information about factors that affect sleep, changes that might help sleep patterns, and how to make those changes. Each session takes about 45 to 60 minutes to complete. During and between sessions, the participant fills out sleep diaries to gather information about daily sleep patterns. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health as well as sleep diaries. Time 1 is just before starting the first session of the modified SHUTi program. Time 2 is about 9 weeks later and Time 3 is about six months after that. The questionnaires will be used to assess the effect of the online program on the participant's sleep and health.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Patient education
Description: A woman assigned to patient education receives access to a website that provides detailed information on habits and environments that may help or hinder sleep. The site can be visited as often as desired. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health, as well as sleep diaries to gather information about her daily sleep pattern. Time 1 is just before first logging into the sleep information website. Time 2 is about 9 weeks later and Time 3 is six months after that. The questionnaires will be used to assess the effect of the sleep information program on the participant's sleep and health.
Study: NCT01047553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol (OT)
Description: 9 μg/dose, Inhaled, twice daily for 52 weeks
Study: NCT02824796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Schema Parent Behavioral Training
Description: A novel protocol for parent whose children suffer from ADHD and comorbidities. The protocol combines elements from Schema Focus Therapy (SFT) and Parent Behavioral Training (PBT)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Behavioral Training
Description: A state of the art Parent Behavioral Treatment (PBT) for Children who suffer from ADHD symptoms
Study: NCT00734877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: M-VTD-PACE
Description: 2 cycles of induction therapy with M-VTD-PACE and PBSC collection after the 1st cycle. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying single dose MEL 200 mg/m2 with adjustments for age and renal function. Consolidation will consist of 2 cycles of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT3-LITE Regimen (L-TT3)
Description: The TT3-LITE Regimen (L-TT3) will employ only 1 cycle of induction therapy with MVTD-PACE and, as in S-TT3, PBSC collection following recovery from this one and only induction treatment. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying fractionated MEL200mg/m2 in 4 successive daily fractions of 50mg/m2 (MEL50 x 4) with addition of VTD with adjustments for age and renal function. Consolidation will consist of only 1 cycle of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
Study: NCT00356304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Participants assigned to motivational interviewing will attend two 1-hour sessions of motivational interviewing over 2 consecutive weeks, followed by a third session 8 weeks later. Motivational interviewing is a type of counselling. Each session is of approximately 1 hour duration.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Participants will continue with their normal treatment regimen as usual.
Study: NCT03437616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tulppa rehabilitation
Description: The intervention includes health education on e.g. healthy diet, weight management, physical activity and psychosocial coping as well as peer discussions and physical exercises.